Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Sanofi (SNY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
08:21pm, Tuesday, 10'th Jun 2025
Sanofi (NASDAQ:SNY ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 4:00 PM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care Conference Call Parti
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
09:00am, Tuesday, 10'th Jun 2025
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to cont
Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr.
06:07pm, Monday, 09'th Jun 2025
Vaccines stocks slipped late Monday after HHS fired all members of a CDC committee in charge of making vaccine suggestions.
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca
03:30pm, Monday, 09'th Jun 2025
The Food and Drug Administration approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus. The decision will allow the company to launc
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
12:30pm, Monday, 09'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to contact D
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
10:00am, Saturday, 07'th Jun 2025
NEW YORK , June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Daniel
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
12:43pm, Friday, 06'th Jun 2025
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
04:00am, Thursday, 05'th Jun 2025
Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
01:45pm, Wednesday, 04'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to cont
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease
11:50am, Wednesday, 04'th Jun 2025
Sanofi's rilzabrutinib earns its fourth orphan drug status from the FDA, this time targeting sickle cell disease.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
08:26am, Tuesday, 03'rd Jun 2025
ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-bo
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
02:51pm, Monday, 02'nd Jun 2025
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
01:00pm, Monday, 02'nd Jun 2025
SNY's $9.5 billion deal to acquire BPMC boosts its immunology pipeline and adds fast-growing Ayvakit to its portfolio.
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
12:48pm, Monday, 02'nd Jun 2025
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciar
